Home > Physicians > Medical Education > Med Ed Programs > Pediatric Acute Lymphoblastic Leukemia: Advances in the Management of High-Risk Patients

CME Program

Pediatric Acute Lymphoblastic Leukemia: Advances in the Management of High-Risk Patients

Order CD

http://www.marrow.org/medorder
(no CME credit available)

Program Description

This program will describe the latest in the management of high-risk pediatric acute lymphoblastic leukemia. Dr. Boulad from Memorial Sloan-Kettering Cancer Center will discuss therapeutic strategies employed for the treatment of high-risk ALL patients:

at the time of diagnosis in order to identify patients at very high-risk for relapse
with refractory disease
in relapse

Findings from the recent American Society for Blood and Marrow Transplantation (ASBMT) evidence-based review The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Lymphoblastic Leukemia in Children¹ will also be discussed.

Faculty

Farid Boulad, M.D., Memorial Sloan-Kettering Cancer Center

Learning Objectives

Identify patients at high risk for disease progression at diagnosis, and beyond
List treatment options and outcomes based on prognostic factors
Determine the appropriate timing and use of transplantation and list factors affecting outcome for this therapy
Summarize advances in the management of relapsed/refractory patients, including new agents.
Review findings from recent ASBMT evidence-based review on pediatric ALL¹

Goal

The goal of this program is to improve diagnosis and treatment of pediatric patients with ALL through education on new therapeutic advances including the role and timing of hematopoietic cell transplantation.

Target Audience

This activity is intended for hematologists, oncologists and other health care professionals who are involved in the treatment of patients with pediatric acute lymphoblastic leukemia.

Accreditation and Certification

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Medical College of Wisconsin, the National Marrow Donor Program^® and the Center for International Blood & Marrow Transplant Research^TM. The Medical College of Wisconsin (MCW) is accredited by the ACCME to provide continuing medical education for physicians.

The Medical College of Wisconsin designates this educational activity for a maximum of 1.0 AMA PRA Category 1 credit(s)^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Support

This activity is supported by an educational grant from Genzyme Corporation provided to the National Marrow Donor Program, through its funding partner, The Marrow Foundation^®.

Questions

If you have questions regarding this program, call Renee Ryan at (800)526-7809 ext. 8430.

1 Hahn T, Wall D, Camitta B, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: An evidence-based review. Biol Blood Marrow Transplant 2005; 11(11): 823-861.

E-mail a Friend

Print this Page